Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$13.57M
Enterprise ValueC$12.33
Total Cash (Recent Filing)C$1.83M
Total Debt (Recent Filing)C$696.00K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe company continues to expand its top line despite current profitability pressure. Ongoing prescription-product sales growth provides a revenue base that could support operating leverage if commercialization costs and product mix improve.
Low Financial LeverageConservative leverage limits near-term solvency risk and preserves financial flexibility. The modest debt burden gives Medicure more capacity to fund commercialization or absorb operating volatility than a highly leveraged specialty pharmaceutical company.
Established Commercialization ModelAn existing commercialization platform in two developed healthcare markets provides a durable framework for generating product sales. Its focus on cardiovascular therapies can support specialized market knowledge and repeat distribution capabilities.
Bears Say
Persistent Operating LossesRevenue is not currently sufficient to cover the company’s operating cost base. Sustained negative EBIT and EBITDA reduce financial resilience and indicate that Medicure needs meaningful margin improvement or stronger sales scale to achieve durable profitability.
Negative Cash GenerationCash consumption weakens the company’s ability to self-fund product commercialization and ongoing operations. If negative cash flow persists, Medicure may need to rely on liquidity or external financing, increasing execution and potential dilution risk.
Eroding Shareholder CushionLarge shareholder losses and declining equity reduce the capital cushion that supports the low-leverage balance sheet. Continued deterioration could constrain strategic flexibility over the next several quarters even without a material increase in debt.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$13.57M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Nov 25, 2026 which is in 96 days.
How were Medicure Inc’s earnings last quarter?
Medicure Inc released its earnings results on Aug 14, 2026. The company reported -C$0.137 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Medicure Inc reported an EPS of -C$0.137 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―